CROs offering Phase III Clinical Trials with Biologics (Monoclonal Antibodies)
23 published
23 published CROs match Phase III Clinical Trials and Biologics (Monoclonal Antibodies).
Locations in this set include United States, United Kingdom, China, Australia, Germany, and India.
Capabilities that show up most often in this set: Phase II Clinical Trials, Regulatory Affairs, Biostatistics & Statistical Programming, Phase I Clinical Trials, and Data Management & eClinical.
Matching companies
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
Velocity Clinical ResearchIntegrated clinical research site organization operating 60+ sites across the U.S. and Europe, supporting trials that contributed to 61 FDA-approved products since 1986.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/phase-3-clinical-trials/biologics-monoclonal-antibodies.md